The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of
combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose escalation) and further
evaluate the safety at RP2Rs (Part 2: dose expansion) in participants with advanced
prostate cancer.

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Advanced Prostate Cancer

Genitourinary Cancer

Advanced Solid Tumors

Prostate Neoplasms

Cancer

Advanced Solid Malignancies

Advanced Solid Tumor

Solid Tumor, Adult

Neoplasms

Adenocarcinoma

Advanced Stage Solid Tumors

JNJ-78278343

JNJ-87189401

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

DLTs are specific adverse events (AEs) and are defined as any of the following: high
grade non-hematologic toxicity or hematologic toxicity.

An AE is any untoward medical occurrence in a participant participating in a clinical
study that does not necessarily have a causal relationship with the
pharmaceutical/biological agent under study. Severity will be graded according to the
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector
cell-associated neurotoxicity syndrome events, which will be graded by American Society
for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from
grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe,
Grade 4= life-threatening and Grade 5= death related to adverse event.

Serum samples will be analyzed to determine concentrations of JNJ-87189401.

Number of participants with antibodies to JNJ-87189401 and JNJ-78278343 will be reported.

ORR is defined as the proportion of participants who have a partial response (PR) or
better according to response evaluation criteria in solid tumors (RECIST) version 1.1
without evidence of bone progression according to Prostate Cancer Working Group 3
(PCWG3).

rPFS is defined time from the date of first dose of study drug until the date of
objective disease progression or death, whichever comes first.

PSA response rate is defined as the percentage of participants with a confirmed decline
of PSA of 50 percent (%) or more from baseline.

DOR is defined for participants who achieved response (PR or better) as the time between
the date of initial documentation of response (PR or better) to the date of first
documented evidence of progressive disease, as defined in the PCWG3, or death due to any
cause, whichever occurs first.

Participants will receive JNJ-78278343+JNJ-87189401 escalated sequentially in Part 1 to
select a recommended Phase 2 regimen (RP2R). Participants will receive the combination
treatment at the RP2R in Part 2 in different disease settings.

University of Colorado Anschutz Medical Campus

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

South Texas Accelerated Research Therapeutics, LLC (START)

Centre Leon Berard

Institut Gustave Roussy

Participants will receive JNJ-78278343+JNJ-87189401 escalated sequentially in Part 1 to
select a recommended Phase 2 regimen (RP2R). Participants will receive the combination
treatment at the RP2R in Part 2 (dose expansion).

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer

Trials at a glance

Trials at a glance

Eligibility criteria